Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy.

OBJECTIVE The objective of this study was to test whether monotone worsening of nerve function, attributable to diabetes, can be demonstrated before criteria for diabetic sensorimotor polyneuropathy (DSPN) have been met. Which nerve tests are best? RESEARCH DESIGN AND METHODS From a prevalence cohort of 504 individuals in the Rochester Diabetic Neuropathy study (RDNS), we identified 238 individuals (group 1) who at first examination were without polyneuropathy (DSPN) by a sum score of the normal deviates (from percentiles) of five attributes of nerve conduction of the legs (i.e., their five nerve conduction normal deviate values were <97.5th percentile) and were followed longitudinally two or more times. Of these 238, 90 (group 2) were followed six or more times at yearly or bi-yearly intervals. We compared different nerve tests for the ones most sensitive and reliable in showing latent nerve dysfunction and monotone (the extent to which a variable measured repeatedly over time reveals a significant trend of worsening or improvement). RESULTS In group 1 patients, the mean sum score of five attributes of nerve conduction (sigma 5 NC nds) at baseline was 1.08 and at the last examination (only patients with Sigma 5 NC nds <97.5th percentile) was 3.63, markedly higher than that in healthy subjects (only of individuals with Sigma 5 NC nds <97.5th percentile) (-0.12), indicating a subtle latent shift of nerve conduction tests toward abnormality. Serial evaluations of many individual and especially sum scores of nerve conduction tests in group 2 patients showed statistically significant worsening with time, even when nerve conduction tests were still well within normal limits. Neurologic signs also worsened but barely to significant levels; however, symptoms and quantitative sensation tests did not. Considering the composite score sigma 5 NC nds, 42 (of 90 group 2 patients) showed significant worsening, 22 were still without DSPN by nerve conduction test criteria, and some were even below the 50th percentile at the last evaluation. CONCLUSIONS Subtle and latent functional worsening of nerve conduction can be demonstrated even before nerve conduction test criteria for DSPN have been met. For demonstrating monotone worsening, the order (from best to worst) of tests was: some composite scores of nerve conduction and individual attributes of nerve conduction. We did not show monotone worsening of symptoms or of quantitative sensation test results. In multivariate analysis of risk factors and their association with worsening sigma 5 NC nds, 24-h microalbuminuria (a marker of microvessel disease) was found to be a significant covariate, an indication that the asymptomatic alterations of nerve conduction are meaningful.

[1]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[2]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[3]  D. DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. , 1984, Archives of ophthalmology.

[4]  R. Hamman,et al.  Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. , 1990, American journal of epidemiology.

[5]  Is there a glycemic threshold? , 1997, Archives of internal medicine.

[6]  W. Litchy,et al.  Individual attributes versus composite scores of nerve conduction abnormality: Sensitivity, reproducibility, and concordance with impairment , 2003, Muscle & nerve.

[7]  D. O'Leary,et al.  Relative growth and maturation of axon size and myelin thickness in the tibial nerve of the rat. 2. Effect of streptozotocin-induced diabetes. , 1990, Acta neuropathologica.

[8]  P C O'Brien,et al.  Procedures for setting normal values , 1995, Neurology.

[9]  J. Daube,et al.  Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. , 1985, Brain : a journal of neurology.

[10]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[11]  M. Brownlee Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.

[12]  P. Low,et al.  Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. , 2003, Diabetes.

[13]  E. Marks,et al.  [Diabetic polyneuropathy]. , 1971, Wiadomosci lekarskie.

[14]  P. Dyck,et al.  Longitudinal study of neuropathic deficits and nerve conduction abnormalities in hereditary motor and sensory neuropathy type 1 , 1989, Neurology.

[15]  L. Melton,et al.  The Rochester Diabetic Neuropathy Study , 1991, Neurology.

[16]  D. O'Leary,et al.  Relative growth and maturation of axon size and myelin thickness in the tibial nerve of the rat , 2004, Acta Neuropathologica.

[17]  M. Nathan,et al.  Effect of intensive diabetes treatment on nerve conduction in the diabetes control and complications trial , 1995, Annals of neurology.

[18]  L. Melton,et al.  The Rochester Diabetic Neuropathy Study , 1992, Neurology.

[19]  Nish Chaturvedi,et al.  Vascular risk factors and diabetic neuropathy. , 2005, The New England journal of medicine.

[20]  W. Litchy,et al.  Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort , 1997, Neurology.

[21]  F. Buchthal,et al.  Electrophysiological studies in diabetic neuropathy , 1970, Journal of neurology, neurosurgery, and psychiatry.

[22]  The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. , 1996, Diabetes.

[23]  R. Heine,et al.  ‘Numbness of the feet’ is a poor indicator for polyneuropathy in Type 2 diabetic patients , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[24]  L. Melton,et al.  Erratum: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study (Neurology (1993) 43 (817-824)) , 1993 .

[25]  J. Pirart Diabetes Mellitus and Its Degenerative Complications: A Prospective Study of 4,400 Patients Observed Between 1947 and 1973 , 1978, Diabetes Care.

[26]  D. Greene,et al.  Diabetic and hypoglycemic neuropathy--a comparison in the BB rat. , 1989, Diabetes research and clinical practice.

[27]  R. Kahn Report and Recommendations of the San Antonio Conference on Diabetic Neuropathy , 1988, Diabetes Care.

[28]  G. Gronseth,et al.  Distal symmetrical polyneuropathy: Definition for clinical research , 2005, Muscle & nerve.

[29]  Ernest W. Johnson,et al.  Motor Nerve Conduction Velocity in Diabetes Mellitus , 1961, Diabetes.

[30]  G. Gronseth,et al.  Distal symmetric polyneuropathy: A definition for clinical research , 2005, Neurology.

[31]  W. J. Litchy,et al.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort , 1993, Neurology.

[32]  James W. Russell,et al.  Sural nerve myelinated fiber density differences associated with meaningful changes in clinical and electrophysiologic measurements , 1996, Journal of the Neurological Sciences.

[33]  W. Litchy,et al.  Variables influencing neuropathic endpoints , 1995, Neurology.

[34]  J. Kimura,et al.  F-wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: multicentre analysis in healthy subjects and patients with diabetic polyneuropathy , 2000, Diabetologia.

[35]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[36]  J. Jakobsen Axonal dwindling in early experimental diabetes. II. A study of isolated nerve fibres , 1976, Diabetologia.

[37]  B. Brenner,et al.  The Kidney in diabetes mellitus , 1989 .

[38]  P. Dyck,et al.  Ultrastructural morphometric abnormalities of sural nerve endoneurial microvessels in diabetes mellitus , 1994, Annals of neurology.

[39]  H. Sone,et al.  Vascular risk factors and diabetic neuropathy. , 2005, The New England journal of medicine.

[40]  J. Najarian,et al.  Long-Term Study of Normal Kidneys Transplanted Into Patients With Type I Diabetes , 1989, Diabetes.

[41]  D. W. Mulder,et al.  The neuropathies associated with diabetes mellitus , 1961, Neurology.

[42]  L. Melton,et al.  Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. , 1999, Diabetes care.